

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

## **CLARIFICATION ANNOUNCEMENT**

Reference is made to the announcement of Consun Pharmaceutical Group Limited (the “**Company**”) dated 13 May 2024 (the “**Announcement**”) relating to notice of a meeting of board of directors (the “**Board**”) for the purpose of considering and approving the declaration of a special dividend and transacting any other business (if any).

The Board noted a clerical error in the English version of the Announcement and would like to clarify that the date of the Board meeting shall be “Friday, 24 May 2024” instead of “Friday, 24 March 2024”.

Save for the aforesaid, the contents of the Announcement remain the same.

By order of the Board of  
**Consun Pharmaceutical Group Limited**  
**An Meng**  
*Chairman*

Hong Kong, 16 May 2024

*As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Xu Hanxing as executive directors; Doctor Zhang Lihua as a non-executive director; and Mr. Feng Zhongshi and Ms. Chen Yujun as independent non-executive directors.*